Seen in competitive
Figure 1: IMMULITE 3G Allergy (2)
Immulite 3G Allergy sIgE
Results due to Biotin
IMMULITE 3G Allergy assay is a competitive assay design, where biotin interference occurs when the patient sample and the biotinylated analyte are co-incubated with the assay-specific antibody or antigen-coated polystyrene beads (the solid phase) (2).
Figure 1: IMMULITE 3G Allergy shows a significant negative bias as concentrations of biotin in the samples increase with all samples reporting as negative (<0.35 kU/L).
In non-competitive indirect assays like the NOVEOS assay, the biotinylated- protein is initially bound to the streptavidin-coated solid phase, followed by incubation with patient sample. Any biotin in the sample, therefore, does not compete for binding.
Figure 2: NOVEOS specific IgE assay (3) shows minimal bias with all samples retaining their positive values (≥0.35 kU/L).
Data on File.
IMMULITE 3G Directions for Use – pull reference from the white paper
The NOVEOS Immunoassay System and NOVEOS Capture
Reagent D001 and D002 are CE-marked and U.S. FDA 510(k) cleared.
Figure 2: NOVEOS Assay (3)
The New Standard
in specific IgE testing,
of current technologies.